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Abstract 
Nowadays, it is crucial to deal with the dosimetry issues in the light of 2013/59 EURATOM recommendation, where it 
is clearly defined that dosimetry will be required even for the targeted radionuclide therapy (TRT). The aim of this pilot 
study was to investigate and to verify the possibilities of dosimetry for patients undergoing first Radioiodine therapy 
(RAIT) using a small single head mobile gamma camera.  
Camera Solo mobile was used for quantitative imaging of 131I accumulation in remnants of patients' thyroids and 131I 
accumulating nodes (neck region). Vials with a known activity of 131I were used to calibrate the system. The patient-
volunteers were around 3 months after thyreoablation due to thyroid carcinoma. The weight of the accumulating 
remnants or nodes was established using ultrasound or roughly estimated using phantom measurements.  
The absorbed doses within remnants or nodes vary from 40 Gy up to 780 Gy with an uncertainty from 25% up to 100% 
depending mainly on the mass of the remnants estimation. A consequent follow-up is being done. The dose assessment 
could be done using cheaper small single-head gammacamera what would safe time of the standard ones. Uncertainty 
is supposed to be significantly reduced by further processes optimization.  
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1 ?????????????  
 
Currently, databases of KNME show high success 
rate in the first year after the radioiodine therapy (up to 
97% of patients treated for the first time at KNME is 
during the first year in remission). However, the data 
indicate increasing number of repeated treatments in 
the range of 2 to 5 years (7-15% of the all patients). 
Percentage of patients undergoing repeated treatment 
reach 20% in the time scale from 5 to 10 years after 
primal therapy. 
Such high number of patients treated more than once 
may be attributed to not completely individualized 
patient therapy planning. It leads to hypothesis that 
remains of the thyroid gland with tumor or lymph 
nodes do not receive a sufficient therapeutic dose. 
Absorbed dose satisfying therapeutic purposes should 
be greater than 300 Gy for thyroid residues and no less 
than 80 Gy for lymph nodes [1], [3], [9]. The absorbed 
dose to the target volume cannot be traced retrospect-
tively and thus in-vivo dosimetric measurements are 
needed for assessment. The absorbed dose is only 
qualitative marker, which has the potential to predict 
subsequent development of disease and that can be 
related to the outcome of therapy in terms of the 
destruction of the target tissue. The absorbed dose is a 
key factor for a design and evaluation of any TRT 
(targeted radionuclide therapy) and this fact is reflected 
in the Council Directive 2013/59 /Euratom issued on 
5th December 2013. In the document it is made clear 
that any therapy should be subjected to planning and 
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verification. In other words, it means that therapy 
planning have to be based on dosimetric 
measurements. The content of this directive will be 
propagated in the national legislation no later than 
February 2018. Based on this requirement, it is 
necessary to study given issue in order to determine 
benefits of planning and verification of the therapy. 
 
1.1 Differentiated thyroid cancer treatment and 
current state-of-the-art 
Differentiated thyroid cancer (DTC) is defined as a 
carcinoma deriving from the follicular epithelium and 
retaining basic biological characteristics of healthy 
thyroid tissue (specific iodine uptake preserved). DTC 
incidence generally shows a noticeable increase [2]. 
Consecutive autopsy studies together with local 
experience at Department of Nuclear Medicine and 
Endocrinology, 2nd Faculty of Medicine, Motol 
University Hospital, Prague (DNME) have shown that 
papillary microcarcinoma is frequent in the general 
population. Improved detection of some of these 
subclinical tumors may be partially responsible for the 
increase in DTC incidence. 
The standard treatment procedure is as follows: total 
or near-total thyroidectomy, respectively, (six level 
lymph nodes dissection and dissection of the lateral-
cervical lymph nodes of the same side as the primary 
lesion). After thyroidectomy, it is now generally 
considered to be contributive to ablate the thyroid 
remnant with 131-radioiodine therapy (RaIT). Ablation 
of thyroid remnant (TRA) allows better management of 
the follow-up of DTC patients. The Thyroglobulin 
serum (hTg) levels should be undetectable or very 
close to zero in case of successful treatment. Potential 
enhancement of hTg serum can be considered as a 
relapse of disease. RAIT can be carried out in 
hypothyroidism state (Thyroid-stimulating hormone 
(TSH) > 30 or after external TSH stimulation). Post-
therapeutic whole body scan and static images of the 
head, neck and thorax, optionally, are acquired 4-8 
days after RAIT. Post-therapeutic examination allows 
us to identify the thyroid remnant and metastases. [1], 
[8], [10] 
Nowadays, RAIT activities are generally empirically 
determined and fixed for each institution. Therefore 
treatment activity is “particularly patient specific” 
(PPS). PPS treatment is usually based on several 
criteria such as disease characteristics and progress, 
patient age, thyroglobulin levels and others. 
Administered activity for radioiodine ablation of post-
surgical thyroid residues vary from 1.11 up to 5.0 GBq 
[1], [8].  
Currently, at the KNME, patients are administered 
with fixed particularly patient specific treatment 
activity (PPSTA) of 3.0; 3.7; 4.4; and 5.5 GBq. PPSTA 
depends on the tumor histology, accumulation of 131I 
within the remnants or nodes, thyreoglobulin 
concentrations, staging of the disease and consideration 
of other medical risk factors. Although, PPSTA is 
obviously popular at some departments conducting 
RAIT and is believed to be optimized and successful, it 
has to be stated that dosimetry is conducted only in few 
cases in different ways making the among-study 
comparison inaccurate. 
The prognosis of the disease is generally excellent 
mainly due to quite time-tested treatment procedures. 
Based on literature research from EANM guidelines 
the 10-year survival rate in cases of distant metastasis 
is approximately 25–40%, the 10-year overall cause-
specific survival for DTC patients as a whole is 
estimated at approximately 85%. Even the lifetime 
recurrence rate is high, reaching 10–30%. Lifelong 
follow-up is proposed for all DTC survivors and 
subsequent therapy in an appreciable number of 
patients should be done.  
As EANM guidelines state, the relatively low 
prevalence of the malignancy and the lengthy overall 
survival of most patients create the need for large 
sample sizes and very long follow-ups. So that 
prospective studies are complicated, especially on new 
therapies. The entire situation flows up into 
recommendation based on clinical experience together 
with literature and limited studies based on observation 
and critical review. EANM guidelines provide citations 
to key studies underlying their recommendations rather 
than formally classifying strength of evidence for 
proposed treatment strategies. [1], [6]. 
 
 
2 ?????????????? ?????? 
The idea of this study was to use appropriate imaging 
device which enable quantitative analysis of the 
acquired image even shortly after administration of 131I 
(high photon fluxes). Basically, it is possible to use 
standard gamma camera [7]. However, the camera time 
is quite expensive and hardly reachable in case of 
necessity of extra examination. Moreover, bigger field 
of view detects more photons and it can be overloaded 
in case of high activities. Therefore, extra device was 
required. Considering relatively small region of interest 
(ROI) – chin, neck, the very upper part of thorax, 
operating small field of view (FOV) gamma camera 
seemed to be more profitable for most of the patients.  
Search for appropriate device was done and DDD 
Company which presented their products at 40th Days 
??? ???????? ????????? ?????????? ????? ???? ?????? ????
cooperation. 
Demo of Single head gama camera Solo mobile was 
lent to DNME for testing. During the testing, it was 
confirmed that this camera is suitable also for the 
dosimetry measurements of the thyroid remnants. 
Consequently, the pilot study was proposed and 
realized.  
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2.1 Experiment outline 
As most of the patients treated at DNME undergo their 
first RAIT (80%), the dosimetry measurements were 
preliminary planned to be set for them. Standard 
schedule of the hospitalization at DNME is as follows: 
? diagnostic administration (DA): 2nd day morning, 
? administered activity: 110 MBq, 
? 131I retention measurements 1 h, 24 h, 48 h after 
DA, 
? accumulation test from 24 h up to 25 h after DA, 
? therapeutic administration (TA) 50 h after DA, 
? dose rate measurement 96 h after TA (radio-
hygienic purpose), 
? WB scintigraphy from 96 h up to 120 h after TA. 
The hospitalization schedule had to be untouched by 
any extra measurements. Regarding this requirement 
first measurement were set just to test the schedule of 
dosimetry measurements in clinical operation.  
Dosimetry schedule was than proposed as follows: 
? measurements of 131I activity in the thyroid 
remnants 1 h, 3 h, 7 h, 22 h, 26 h, 48 h after DA 
(dose rate 1 m from the patient was measured at the 
same time), 
? therapeutic administration (TA) 50 h after DA, 
? measurements of 131I activity in the thyroid 
remnants 5-7 h, 22 h, 30 h, 46 h 55 h 74 h, 94 h and 
124 h after TA (dose rate 1 m from the patient was 
measured at the same time). 
Proposed dosimetry schedule was usually kept up to 
one or two measurements which had to be canceled or 
delayed.  
Participating patient-volunteers were around 
3 months after thyreoablation due to thyroid 
carcinoma. They were asked to participate and all the 
measurements were explained and detailed to them. 
Examination was usually done in separate room 
during diagnostic measurements. The post-therapeutic 
measurement was done in corridor of bed ward as it 
was closer to the patient's rooms. Examination was 
done in the closest patient-to-detector geometry (see  
Fig. 1). Patients' neck distance from the detector was 
measured so distance correction could be done. 
2.2 Imaging and activity determination 
Measurements of 131I accumulated in the remnants of 
patients' thyroids and 131I accumulating nodes (neck 
region) were done by the Solo Mobile camera.  
Two types of collimators - MEGP (medium energy 
general purpose) and HEGP (high energy general 
purpose) were tested. This was done due to quite 
problematic operation with the HEGP collimators. The 
first group (six patients) was examined using the 
MEGP collimator (one patient was excluded because of 
repeated therapy); HEGP was used for the other group 
(five patients). The first group of patients underwent 
more than 5 measurements after diagnostic adminis-
tration. Consequently, more than five measurements 
were done after therapeutic administration. For the 
second group six measurements after diagnostic and 
seven measurements after therapy were performed.  
Vials with a known activity of 131I were used to do 
a basic calibration of the camera. Detected counts 
dependence on activity in various source-to-camera 
within and without PMMA neck phantom. Calibration 
then served to determine the activity of 131I within 
lesions from the static scintigraphy image. During the 
first 72 hours of measurement standardized activity 
was present within the FOV together with patient (see  
Fig. 2). This enabled more direct calculation of the 
lesions activity without the need of dead time 
correction and demands for detailed calibration 
measurements. Activity in lesion Al for each 
measurement was then determined as in equation (1). 
Here AS is the standard activity, Cl is counts within 
the ROI in lesion, CS is counts in the ROI of standard, 
Bgl, and BgS are pixel-normalized background counts 
(see Fig. 2). Further, d is distance correction. Depth 
correction of the lesion was neglected.  
2.3 Mass of the lesion 
The weight of the accumulating remnants or nodes 
was established using volume measured by ultrasound. 
 
 
Fig. 1: Patient position in front of the camera. 
 
 
Fig. 2: Standard position within the FOV. 
dSA
SC
lC
lA ???
?
?
SBg
lBg                                     (1) 
Standard 
Lesions 
BgS Bgl 
ClS 
Cl 
ORIGINAL RESEARCH  
85 
 
For simplification, lesions and nodes are considered to 
be ellipsoids, thus the volume is equal to (4/3)?abc in 
the first approximation and the density was set to 1 g 
per ccm. In case that the scintigraphy image didn’t 
correlate with sonography, volume of the accumulating 
lesions was roughly estimated using phantom 
measurements or known volume of similarly 
accumulating lesions of other patients. Mass of the 
lesions estimation error was proposed to be from 30% 
up to 50% based on the physicians’ experiences.  
2.4 Dose determination 
Using quantitative imaging for activity determination 
within the remnants of thyroid and nodes cumulated 
activity was calculated as an integral of the curve 
fitting the data (example Fig. 3). Calculation of 
cumulated activity was usually done for the curve from 
8 hours up to 200 hours (extrapolation) after treatment 
administration. First 8 hours of cumulated activity 
(uptake) was approximate to be 2/3 of the activity after 
8 hours. 
Absorbed dose from emitted electrons was 
determined and was proposed as the therapeutic dose 
from radioiodine therapy according the equation (2). 
Absorbed dose due to photons was neglected as for 
such small lesions (less than 1 ccm) is insignificant. 
3 ??????? 
Absorbed doses were determined for all the 
participating patients. Results are in Tab. 1 and Tab. 2. 
Red-dyed cells correspond to lesions where either 
lesions mass was estimated or no scintigraphy 
correlation with sonographic examination was 
observed.  
 
Tab. 1: Dosimetry results for the MEGP measurements. 
MEGP Right remnants 
Left 
remnants 
Right 
nod 
Left 
nod 
A 
[MBq] 
m 
1958 
Vol 
[ml] 0.2 0.42  0.58 4450 
D 410  Gy 340  Gy 740  Gy 
f 
1991 
Vol 
[ml] 0.3 0.4   3720 
* D - 135  Gy    
f 
1960 
Vol 
[ml] 0.53 0.59  0.69 4460 
D 400 Gy 550  Gy 180 Gy 
f 
1984 
Vol 
[ml]    0.12 3700 
D 115  Gy 
f 
1988 
Vol 
[ml]   ? 0.12 2970 
D D  [Gy]: <15,40> 340 Gy 
 
 
 
In the tables results in <,> brackets correspond to the 
lowest and the highest dose estimation using the 
highest expectable lesion volume and the lowest 
expectable lesion volume based on estimation from 
patient similar medical finding. Patients marked with * 
are supposed to come for repeated treatment because 
the treatment dose calculated from our measurements is 
lower than the generally recognized limit 300 Gy for 
thyroid tissue and 80 Gy for nod (see [1]). 
4 ?????????? 
As this work was mainly intended to be a pilot study 
most of the errors are only an estimation based on 
limited number of measurements.  
 
 
 
 
 
Fig. 3: Example of fitting measured data for multiple 
accumulating lesions. 
Tab. 2: Dosimetry results for the HEGP measurements. 
HEGP Right remnants 
Left 
Remnants 
Right 
nod 
Left 
nod 
A 
[MBq] 
m 
1967 
Vol 
[ml] 0.54    3710 
D 520 Gy 
m 
1965 
Vol 
[ml] 0.14 0.05 ? 3720 
 D 650  Gy 590 Gy <80, 400>  
m 
1991 
Vol 
[ml] 0.6 0.4   3720 
* D 240 Gy 280  Gy    
f 
1960 
Vol 
[ml] <0. 0.01   3730 
* D <80,330> 310  Gy    
f 
1961 
Vol 
[ml] 0.06 0.11   3720 
D no Ac. 780  Gy 
 
[J]19101,602192000[eV]
Tm
SA
~
T)(TD
?????
         (2) 
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The smallest error (10%) is supposed to be in the 
activity determination because standard with known 
activity was used in the FOV and neck-to-camera 
distance correction was applied. Lesions volume 
determination using sonography is also quite small 
(from 5% to 15%) influenced mainly by the physician. 
Uncertainty from data fitting and cumulative activity 
determination is supposed to be lower than 15%. 
Combined error resulting from limited time for 
calibration and first 24 h after TA administration 
measurements is supposed to be less than 20%. So that 
the pilot-study-lowest combined error was estimated to 
be 25% for patients where the sonography is correlated 
with scintigraphy image. However in cases, where the 
sonography is not correlated with the scintigraphy (the 
nod or remnant can’t be measured than), it is hard to do 
any dose calculation because the mass of the lesion is 
only estimate. Nevertheless, it is still possible to 
presume that the accumulating lesion has a limited 
mass due to physicians’ long-professional-life 
experiences. Based on that mass was estimated 
conservatively (the lowest dose) as a ten times larger 
remnant than the correlated one and optimistic 
estimation was only two or three times larger remnant 
than the correlated one. This “estimation” could vary 
the dose calculation than for more than +/- 100% so 
that 100% error is to be considered than. 
This estimation is still very problematic and the error 
is large so that interval of dose is putted down and 
marked by pink color.   
5 ???????????? 
Results show that most of the patients are 
administered with sufficient therapeutic activity. 
Nevertheless; three out of ten patients are supposed to 
come back for repeated treatment (administered 
activity was unable to deliver sufficient treatment 
dose). Quite big dispersion through the studied groups 
was observed and it is in an agreement with recent 
findings. 
 
 
????????????????  
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